Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2016
17th World Conference on Lung Cancer
Access to all presentations that occur during the 17th World Conference on Lung Cancer in Vienna, Austria
Presentation Date(s):- Dec 4 - 7, 2016
- Total Presentations: 2466
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
OA03 - Immunotherapy Checkpoint Inhibitors in Advanced NSCLC
- Type: Oral Session
- Track: Chemotherapy/Targeted Therapy/Immunotherapy
- Presentations: 8
- Moderators:L. Crinò
- Coordinates: 12/05/2016, 11:00 - 12:30, Hall C8
-
+
OA03.05 - Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057 (Abstract under Embargo until December 5, 7:00 CET)
11:45 - 11:55 | Author(s): S. Peters
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA05 - Treatment Advances in SCLC
- Type: Oral Session
- Track: SCLC/Neuroendocrine Tumors
- Presentations: 8
- Moderators:A. Ardizzoni
- Coordinates: 12/05/2016, 14:20 - 15:50, Strauss 2
-
+
OA05.04 - Discussant for OA05.01, OA05.02, OA05.03
14:50 - 15:05 | Author(s): L. Horn
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA04 - HER2, P53, KRAS and Other Targets in Advanced NSCLC
- Type: Mini Oral Session
- Track: Advanced NSCLC
- Presentations: 12
- Moderators:B. Han
- Coordinates: 12/05/2016, 16:00 - 17:30, Lehar 3-4
-
+
MA04.02 - Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study
16:06 - 16:12 | Author(s): L. Gandhi
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA09 - Immunotherapy Combinations
- Type: Mini Oral Session
- Track: Chemotherapy/Targeted Therapy/Immunotherapy
- Presentations: 12
- Moderators:M. Sebastian
- Coordinates: 12/06/2016, 14:20 - 15:50, Strauss 2
-
+
MA09.05 - Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial
14:50 - 14:56 | Author(s): M.D. Hellmann
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.03a - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 72
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.03a-049 - Response to Salvage Chemotherapy Following Exposure to PD-1 Inhibitors in Patients with Non-Small Cell Lung Cancer
14:30 - 14:30 | Author(s): P.D. Leger
- Abstract
Loading...
-
+
P2.06 - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Scientific Co-Operation/Research Groups (Clinical Trials in Progress should be submitted in this category)
- Presentations: 47
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.06-007 - A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non–Small Cell Lung Cancer (NSCLC)
14:30 - 14:30 | Author(s): R.C. Doebele
- Abstract
Loading... -
+
P2.06-011 - Phase 2 Study of MM-121 plus Chemotherapy vs. Chemotherapy Alone in Heregulin-Positive, Locally Advanced or Metastatic NSCLC
14:30 - 14:30 | Author(s): L.V. Sequist
- Abstract
Loading... -
+
P2.06-021 - Efficacy and Safety of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment in Subjects with EGFRMut+ NSCLC
14:30 - 14:30 | Author(s): R.J. Kelly
- Abstract
Loading...
-
+
P3.02a - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 37
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02a-001 - Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC
14:30 - 14:30 | Author(s): L. Horn
- Abstract
Loading...
-
+
P3.02b - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 126
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02b-052 - Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403
14:30 - 14:30 | Author(s): S.B. Goldberg
- Abstract
Loading...
-
+
P3.02c - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 103
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02c-024 - Detection of Novel Activating FGFR Rearrangements, Truncations, and Splice Site Alterations in NSCLC by Comprehensive Genomic Profiling
14:30 - 14:30 | Author(s): S.M. Gadgeel
- Abstract
Loading... -
+
P3.02c-041 - IMpower133: A Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC
14:30 - 14:30 | Author(s): S.V. Liu
- Abstract
Loading... -
+
P3.02c-051 - A Pre-Treatment Serum Test Based on Complement and IL-10 Pathways Identifies Patients Benefiting from the Addition of Bavituximab to Docetaxel
14:30 - 14:30 | Author(s): D.E. Gerber
- Abstract
Loading...
